Skip to main content
. 2021 Sep 14;18(5):1049–1061. doi: 10.1080/15548627.2021.1968228

Figure 1.

Figure 1.

Starvation and AAD induce FAM134B2 through a pathway independent of CEBPs, EIF2AK4 and MTOR. (A, B) RETREG1 and FAM134B2 mRNA expression in HeLa cells treated with EBSS or complete DMEM (CM). (C) FAM134B2 protein expression in HeLa cells treated with EBSS. HeLa cells were treated with EBSS for 6 h. (D, E) RETREG1 and FAM134B2 mRNA expression in HeLa cells treated with leucine-deficient media. HeLa cells were treated with DMEM lacking Leucine for 6 h. (F, G) RETREG1 and FAM134B2 mRNA expression in HeLa cells treated with a Histidine antagonist, HisOH. (H) CEBP mRNA expression in HeLa cells treated with HisOH. HeLa cells were treated with DMEM containing 2 mM HisOH for 6 h. (I) CEBP mRNA expression in HeLa cells treated with CEBP RNAi. (J) FAM134B2 mRNA expression in HeLa cells treated with CEBP RNAi in the presence of HisOH. HeLa cells were treated with 10 nM RNAi in the presence of RNAi Max for 16 h and then treated with 2 mM HisOH for 6 h. (K–M) EIF2AK4, FAM134B2 and DDIT3 expression in HeLa cells treated with EIF2AK4 RNAi and HisOH. HeLa cells were treated with 10 nM RNAi in the presence of RNAi Max for 16 h and then treated with 2 mM HisOH for 6 h. (N, O) FAM134B2 and DDIT3 expression in HeLa cells treated with ISRIB and HisOH. HeLa cells were treated with 200 nM ISRIB for 2 h and then treated with 2 mM HisOH for 6 h. (P) Effect of MTOR on the mRNA expression of FAM134B2. HeLa cells were treated with MTOR inhibitors [rapamycin (Rapa), 100 nM and Torin 1, 1 μM] for 6 h. ***P < 0.001.